Neuraminidase inhibitors for critically ill children with influenza

Pediatrics

Volumn 132, Issue 6, 2013, Pages

  Louie, Janice K ^a   Yang, Samuel ^a   Samuel Dr , Michael C ^a   Uyeki, Timothy M ^b   Schechter, Robert ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiviral; Children; Critically ill; Influenza; Mortality; Neuraminidase inhibitor; Pediatric; Pediatric ICU

Indexed keywords

SIALIDASE INHIBITOR; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; OSELTAMIVIR; PERAMIVIR; SIALIDASE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CRITICAL ILLNESS; DISEASE SEVERITY; EARLY INTERVENTION; FEMALE; HUMAN; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; EVALUATION STUDY; HEALTH SURVEY; HOSPITALIZATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; INFLUENZA, HUMAN; INTENSIVE CARE; ISOLATION AND PURIFICATION; MULTIVARIATE ANALYSIS; NEWBORN; PANDEMIC; PRESCHOOL CHILD; PROCEDURES; RISK; STATISTICAL MODEL; UNITED STATES;

ADOLESCENT; CALIFORNIA; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; CYCLOPENTANES; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GUANIDINES; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INFLUENZAVIRUS B; INTENSIVE CARE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NEURAMINIDASE; ODDS RATIO; OSELTAMIVIR; PANDEMICS; POPULATION SURVEILLANCE; TREATMENT OUTCOME; ZANAMIVIR;

EID: 84889030377     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-2149     Document Type: Article

References (30)

1. Louie JK, Acosta M, Winter K, et al California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896- 1902
2. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-1719
3. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children - Southern California, March- April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(15):400-402
4. Garg S, Fry AM, Patton M, Fiore AE, Finelli L. Antiviral treatment of influenza in children. Pediatr Infect Dis J. 2012;31(2):e43-e51
5. Louie JK, Gavali S, Acosta M, et al California Pandemic (H1N1) Working Group. Children hospitalized with 2009 novel influenza A (H1N1) in California. Arch Pediatr Adolesc Med. 2010;164(11):1023-1031
6. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Available at: www.cdc.gov/H1N1flu/recommendations.htm. Accessed October 27, 2011
7. Fiore AE, Uyeki TM, Broder K, et al Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62
8. Centers for Disease Control and Prevention. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. January 21, 2011;60(RR01):1-24. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/ rr6001a1. htm. Accessed October 13, 2013
9. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965
10. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163(14): 1667-1672
11. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935-1944
12. Rodríguez A, Díaz E, Martín-Loeches I, et al; H1N1 SEMICYUC Working Group. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother. 2011; 66(5):1140-1149
13. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: A case series. Lancet. 2008;372(9640):744- 749
14. Viasus D, Paño-Pardo JR, Pachón J, et al; Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A (H1N1) virus infection. Chest. 2011;140(4): 1025-1032
15. Higuera Iglesias AL, Kudo K, Manabe T, et al. Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: A retrospective study in Mexico. PLoS One. 2011;6 (7):e21838
16. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65(6):510-515
17. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: Analysis of a Global Patient Registry. J Infect Dis. 2010; 202(8):1154-1160
18. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS ONE. 2009;4(6):e6051
19. McGeer A, Green KA, Plevneshi A, et al Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568- 1575
20. Treanor JJ, Hayden FG, Vrooman PS, et al US Oral Neuraminidase Study Group. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA. 2000;283(8):1016-1024
21. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012;55(9):1198-1204 doi: 10.1093/cid/cis636
22. Muthuri SG, Myles PR, Venkatesan S, Leonardi- Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009- 2010 influenza A(H1N1) pandemic: A systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553-563
23. Launes C, García-García JJ, Jordán I, Martínez- Planas A, Selva L, Muñoz-Almagro C. 2009 Influenza A H1N1 infections: delays in starting treatment with oseltamivir were associated with a more severe disease. Pediatr Infect Dis J. 2011;30(7):622-625
24. Eriksson CO, Graham DA, Uyeki TM, Randolph AG. Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A. Pediatr Crit Care Med. 2012;13 (6):625-631
25. Bueno M, Calvo C, Méndez-Echevarría A. Oseltamivir Treatment for Influenza in Hospitalized Children without Underlying Diseases. Pediatr Infect Dis J. 2013;32(10):1066-1069
26. Coffin SE, Leckerman K, Keren R, Hall M, Localio R, Zaoutis TE. Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: A retrospective cohort study. Pediatr Infect Dis J. 2011;30(11):962-966
27. Farias JA, Fernández A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36(6):1015-1022
28. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis. 2012;55(1):26-32
29. Garg S, Chaves SS, Pérez A, et al. Reduced influenza antiviral treatment among children and adults hospitalized with laboratoryconfirmed influenza infection in the year after the 2009 pandemic. Clin Infect Dis. 2012;55(3):e18-e21
30. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53(4):326-333